Outlook Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Outlook Therapeutics, Inc. (OTLK) is a clinical-stage biopharmaceutical company focused on developing and commercializing ophthalmic formulations of bevacizumab for retinal diseases; its lead product candidate, ONS-5010/LYTENAVA (bevacizumab-vikg, bevacizumab gamma), targets wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO) via intravitreal injection as a recombinant humanized monoclonal antibody that binds vascular endothelial growth factor (VEGF) to inhibit endothelial cell proliferation, vascular leakage, and neovascularization in the retina. LYTENAVA has received Marketing Authorization from the European Commission and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for wet AMD treatment, with commercial launches planned in select European markets including Germany and the UK in the second quarter of 2025; in the United States, ONS-5010 remains investigational, with the Biologics License Application (BLA) resubmitted to the FDA in November 2025 following a Complete Response Letter in August 2025, accepted for review with a PDUFA target action date of December 31, 2025. Founded in 2010 and headquartered in Iselin, New Jersey, the company--formerly known as Oncobiologics, Inc. until its rebranding in November 2018--employs approximately 23 people and operates primarily in the United States, European Union, and United Kingdom, serving retina specialists and patients with retinal conditions through its pipeline emphasizing anti-VEGF therapies to address unmet needs in ophthalmology. Recent developments include a strategic commercialization collaboration with Cencora (formerly AmerisourceBergen) for global market access, third-party logistics, distribution, and pharmacovigilance services to support LYTENAVA launches; closure of a private placement in March 2024 raising up to $159 million led by Great Point Partners LLC with participation from investors including GMS Ventures, Altium Capital, Armistice Capital, and others to fund clinical programs like the NORSE EIGHT trial and general corporate purposes; and presentation of positive efficacy and safety data from NORSE EIGHT at conferences in late 2025.
Company News
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
Oncobiologics Q3 Earnings Call Highlights
Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
Oncobiologics Q3 Earnings Call Highlights
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
Reviewing Oncobiologics (NASDAQ:OTLK) and Pasithea Therapeutics (NASDAQ:KTTA)
OTLK Up More Than 300% in 3 Months: Here's What You Should Know
Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?
Outlook: 'Hold' - Caution On LYTENAVA FDA Approval And Cash Needs
US FDA approves Outlook Therapeutics' eye disease drug
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD